米国企業
EAGLE PHARMACEUTICALS, INC.

EAGLE PHARMACEUTICALS, INC.EGRX

時価総額

$6181.8万

PER

	2014年 9月30日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日
Net income (loss)	-18	3	81	52	32	14	12	-9	36
Deferred income taxes	-	-	-30	17	-2	0	-2	-4	-8
Depreciation	0	-	1	1	1	2	1	1	1
Operating Lease, Right-of-Use Asset, Amortization Expense	-	-	-	-	-	-	1	1	1
Amortization of Intangible Assets	-	-	1	3	3	3	3	3	11
Stock-based compensation expense	1	4	10	15	19	22	25	20	16
Fair value adjustments on equity investment	-	-	-	-	-	-	-5	-6	-4
Amortization of debt issuance costs	-	-	-	0	0	0	0	0	0
Fair Value Adjustment On Accelerated Share Repurchases	-	-	-	-	-	-	3	-	-
Fair value adjustments related to derivative instrument	-	-	-	-	-	-	-	1	-1
Gain on fair value adjustments related to debt	-	-	-	-	-	-	-	-	0
Accretion of discount on convertible promissory note	-	-	-	-	-	-	-	0	-
Loss on write-off of promissory note	-	-	-	-	-	-	-	-	-4
Accounts receivable	2	14	16	12	13	-18	3	-10	31
Inventories	1	14	-12	2	6	-2	2	14	8
Prepaid expenses and other current assets	-0	0	9	-2	-5	5	-11	3	5
Accounts payable	3	0	11	-8	-2	-4	1	10	3
Accrued expenses and other liabilities	7	12	-0	-9	8	4	-4	8	44
Other assets and other long-term liabilities, net	-	-	-	-	-	-	-	-	19
Net cash provided by operating activities	-14	-10	53	59	52	56	49	28	51
Purchase of Acacia, net of cash acquired	-	-	27	-	-	-	-	-	74
Purchase of equity investment security	-	-	-	-	-	-	-	-	13
Purchase of property and equipment	0	2	2	4	0	1	1	0	0
Net cash used in investing activities	-20	-2	-46	-5	-0	-1	-18	-5	-87
Repurchases of common stock	-	-	37	44	73	18	35	21	18
Proceeds from Issuance of Debt	-	-	-	50	-	-	110	-	30
Repayment of existing revolving credit facility	-	-	-	-	-	-	110	-	15
Debt proceeds	-	-	-	-	-	-	-	-	50
Payment of debt	-	-	-	1	4	6	5	8	52
Payment of debt financing costs	-	-	-	1	-	0	-	-	1
Payment of employee withholding tax upon vesting of stock-based awards	-	-	-	-	5	0	2	2	1
Proceeds from Stock Options Exercised	0	1	4	4	9	0	4	2	2
Net cash used in financing activities	46	56	-34	8	-88	-24	-38	-28	-6
Net decrease in cash and cash equivalents	-	-	-	-	-	31	-7	-5	-42
Income taxes, net	-	0	3	11	2	7	6	10	28
Interest	-	-	-	-	-	2	2	1	2
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	-	-	-	-	-	4	1	0	-